Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07073352 · ClinicalTrials.gov registry record · NA
ACEs, SIRT1, and Premature Vascular Aging in Humans
A NA study of Endothelial Dysfunction and Adverse Childhood Experiences, sponsored by Nathaniel Jenkins.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07073352 is a NA study of Endothelial Dysfunction and Adverse Childhood Experiences that is actively recruiting participants, run by Nathaniel Jenkins. The registered enrollment target is 30 participants, below the 92-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07073352, a NA study of Endothelial Dysfunction and Adverse Childhood Experiences, is actively recruiting participants, sponsored by Nathaniel Jenkins.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Adverse childhood experiences (ACEs) are directly related to cardiovascular morbidity and mortality, and impaired vascular endothelial function (VEF) is an independent predictor of future cardiovascular disease (CVD) risk \[1, 2\]. Previous work from our lab (IRB 202010095) and others \[3\] demonstrates impaired VEF in young adults with prior exposure to ACEs even in the absence of clinical CVD risk factors. Sirtuin 1 (SIRT1) is a class III histone deacetylase (HDAC) that plays a role in regulating vascular homeostasis and reductions in SIRT1 are associated with age-related endothelial dysfunction \[4\]. We have shown that ACEs-related impairments in VEF are accompanied by reductions in SIRT1 \[5\]. However, the mechanisms by which ACE exposure promotes VEF remain unknown. The goal of this project is to establish proof of concept that alterations in vascular SIRT1 expression and activity mediate premature vascular aging in individuals with \>=4 ACEs compared to those with 0 ACEs and that, because NAD+ is an essential substrate for SIRT1, increasing NAD+ bioavailability will restore VEF in those with \>=4 ACEs. Thus, we will use a robust translational approach coupling in vivo and in vitro measures of endothelial function, inflammation, oxidative stress, and SIRT1 expression and activity in young adults with (n=30-35) versus without (n=30-35) ACE exposure in a cross-sectional study, and during a randomized controlled trial employing a novel 4-week nicotinamide riboside (NR) supplementation approach to increase SIRT1 activity by increasing cellular NAD+ in ACE+ (n=15/group) to accomplish the following specific aims: 1. Determine the mechanisms by which ACE exposure alters the regulation of VEF by SIRT1. We hypothesize that compared to those without ACEs (ACE-), ACE+ will have (H1a) elevated endothelial oxidative stress and inflammation, (H1b) accompanied by reduced endothelial SIRT1 expression and increased p66SHC expression and acetylation of p65 and p53, (H1c) in
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Nicotinamide Riboside
Study Locations (1)
Iowa
- Integrative Laboratory of Applied Physiology and Lifestyle Medicine - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07073352
The ClinicalTrials.gov registry entry for NCT07073352 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (67% lower). The listed sponsor is Nathaniel Jenkins, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07073352 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT07073352 about?
NCT07073352 is a clinical study titled "ACEs, SIRT1, and Premature Vascular Aging in Humans". Adverse childhood experiences (ACEs) are directly related to cardiovascular morbidity and mortality, and impaired vascular endothelial function (VEF) is an independent predictor of future cardiovascular disease (CVD) risk \[1, 2\]. Previous work from our lab (IRB 202010095) and others \[3\] demonstr...
What is the current status of trial NCT07073352?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-03-27. Estimated completion is 2027-06-30.
What conditions does trial NCT07073352 study?
This clinical trial studies the following conditions: Endothelial Dysfunction, Adverse Childhood Experiences.
What interventions are being tested in trial NCT07073352?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Nicotinamide Riboside (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07073352?
This trial is sponsored by Nathaniel Jenkins, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07073352 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Sodium Lowering Vascular Effects Trial
RECRUITING · NA
-
NightWare and Cardiovascular Health in Veterans With PTSD
RECRUITING · NA
-
Bright Light Exposure in Surgical Patients
RECRUITING · NA
-
Microvascular Dysfunction in Obesity
RECRUITING · NA
-
Inspiratory Muscle Strength Training for Lowering Blood Pressure and Improving Endothelial Function in Postmenopausal Women: Comparison With "Standard of Care" Aerobic Exercise
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.